Last updated 2026-11-10
- Raised $35M Public Offering, Oct 2020
- Raised $43.7M PIPE, Mar 2020
- Raised $20M Public Offering, Mar 2025
Total raised
$159.9M
Last: Public Offering 2021-02
Stage
Public
Founded
1993
Headcount
230
HQ
Hackensack, United States
Sector
Health Tech & Life Sciences
About
Protalix is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases. The company is advancing promising candidates leveraging its expertise in protein therapeutics through its proprietary, commercial-scale ProCellEx® plant cell-based protein expression system, as well as its chemical and genetic modification capabilities, including PEGylation. With two approved drugs already making an impact, Protalix is committed to expanding its pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.
Funding history · 9 rounds · $159.9M total
9 events/rounds · $159.9M Total Funding: $71.0M in Private Equity, $75.0M in Public Equity
Mar 2025
Public Offering
$20.0M
EDGAR filing SEC-EDGAR 8-K
Jul 2021
Public Offering
$20.0M
EDGAR filing SEC-EDGAR 424B5
Oct 2020
Public Offering
$35.0M
EDGAR filing SEC-EDGAR 8-K
Mar 2020
PIPE
$43.7M
EDGAR filing SEC-EDGAR 8-K
Mar 2011
Apr 2008
Grant
Undisclosed
prior (startupim db)
Dec 2006
Public Offering
Undisclosed
wikipedia.org
Jul 2005
★ Phillip Frost★ Ziff Asset Management LPTamares CapitalDocor International BVAtara Technology Ventures Ltd.existing Protalix shareholders
Oct 2004
Grant
$6.0M
biospace.com
Offices
Hackensack, United States · HQ / main office
Q&A
- What is Protalix BioTherapeutics' primary focus?
- Protalix BioTherapeutics is a biopharmaceutical company that develops plant cell-expressed enzyme replacement therapies for rare lysosomal storage disorders.
- When was Protalix BioTherapeutics founded?
- Protalix BioTherapeutics was founded in 1993.
- What is Protalix BioTherapeutics' current employee count?
- Protalix BioTherapeutics has 201-500 employees.
- What was Protalix BioTherapeutics' most recent public offering?
- In March 2025, Protalix BioTherapeutics had a Public Offering that raised $20,000,000.
- Which investors participated in Protalix BioTherapeutics' C Round in July 2005?
- Protalix BioTherapeutics' C Round in July 2005 included investments from Phillip Frost.
- What was the amount raised in Protalix BioTherapeutics' PIPE round in March 2020?
- In March 2020, Protalix BioTherapeutics raised $43,700,000 in a PIPE round.
- Who is the current President & Chief Executive Officer of Protalix BioTherapeutics?
- Moshe Manor serves as the President & Chief Executive Officer of Protalix BioTherapeutics.
- What is Protalix BioTherapeutics' proprietary technology for protein expression?
- Protalix BioTherapeutics utilizes its proprietary, commercial-scale ProCellEx® plant cell-based protein expression system for protein therapeutics.
Team · 15
Yoseph Shaaltiel
Founder · Board Member & Vice President, Research and Development
Moshe Manor
President & Chief Executive Officer
Gilad Mamlok
Senior Vice President & Chief Financial Officer
Yaron Naos
Senior Vice President, Operations
Ori Kalid
Vice President, Research and Development
Shoshi Tessler
Vice President, Clinical Development & Regulatory Affairs
Tanya Gershanik
Vice President, Quality Affairs
Yael Fellous
Vice President, Human Resources
Eliot Forster
Chairman of the Board of Directors
Amos Bar Shalev
Director
Shmuel “Muli” Ben Zvi
Director
Pol F. Boudes
Director
Christian Elze
Director
Gwen Melincoff
Director
Aharon Schwartz
Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Highlights
Patents
Tags
antibodiesoral-drugspharmaceuticalsproteinsgenetic-disordersplant-proteininflammatory-diseasespharma-companiesdrug-development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | protalix.com |
|---|---|
| linkedin.com/company/739969 | |
| X / Twitter | twitter.com/protalix_bio |
| Wikipedia | en.wikipedia.org/wiki/Protalix_BioTherapeutics |
| Wikidata | wikidata.org/wiki/Q7251166 |
Identifiers & details
| Legal name | Protalix BioTherapeutics Inc. |
|---|---|
| Founded | 1993 |
| Employees (exact) | 230 |
| Wikidata QID | Q7251166 |
Radar intelligence
Web history (Wayback)
| Domain | protalix.com |
|---|
Wikidata
| QID | Q7251166 |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 511903288 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1993-12-27 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 3 — people (2), charge (1) |
| Registered address | סנונית 2 כרמיאל |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-24 | עדכון דירקטורים-הסרת דירקטור |
| 2025-11-24 | עדכון דירקטורים-הוספת דירקטור |
| 2025-12-17 | רישום שעבוד |